INTRODUCTION {#s1}
============

Approximately 20--30% of all metastatic renal cell carcinomas (mRCCs) are synchronous mRCCs (SMs), a newly diagnosed metastatic entity. A further 20% of mRCCs are metachronous mRCCs (MMs), a recurring or progressed localized RCC that has metastasized after curative surgical therapy \[[@R1], [@R2]\]. In past decades, the standard therapeutic approach for mRCC was systemic therapy using cytokines, and a shift toward targeted therapy (TT) has occurred over the last recent decade owing to an increased understanding of the pathogenesis of RCC provided by next-generation sequencing \[[@R3]\]. In contrast to cytokine therapy, recently developed TT focuses more on the treatment of a highly vascularized and immune-related tumor microenvironment \[[@R3], [@R4]\]. However, the different pathophysiologic microenvironments and immune-related conditions of different metastatic types produce various therapeutic responses to TT in the clinical context of mRCC \[[@R4]\]. This has resulted in a 0--20% 5-year survival rate, which is considered unacceptable by most clinicians \[[@R3], [@R5], [@R6]\].

The response of SM and MM to TT is variable owing to the pleomorphic nature of RCC and diverse tumor burden levels associated with the disease \[[@R7], [@R8]\]. MM probably involves fewer oncogenic events than SM, especially in primary tumors. The dormant tumor cells in MM experience oncogenic activity, which stimulates them to form and grow at the site of metastases at a certain point in time following nephrectomy \[[@R4], [@R9]\]. Previous immunohistochemical tissue studies have demonstrated that SM has distinct phenotypes with different oncogenic events, resulting in worse prognoses than MM \[[@R4], [@R10]\]. These unpredictable and diverse characteristics of mRCC, especially in different metastatic types, are difficult to predict from the primary tumor alone, but easier to predict based on combined data from metastatic tumors. Therefore, understanding the prognostic differences between SM and MM is important for developing strategies for treating mRCC in the TT era \[[@R11], [@R12]\].

The general consensus is that the prognosis of MM is better than that of SM. However, no objective data regarding this issue have been published, except for some case reports, retrospective studies of specific organ metastases, and genetic analyses of specific RCC histological types \[[@R4], [@R13]-[@R16]\]. Clinicians require relevant prognostic data in order to understand the prognoses of patients with MM or SM and to treat them effectively with TT.

With the above in mind, this study aimed to retrospectively analyze the progression-free survival (PFS) provided by first-line VEGF-TT and the overall survival (OS) of MM and SM patients according to Heng risk groups \[[@R10]\]. The two groups were divided into sub-groups based on treatment-free intervals (TFIs) and analyzed further. Finally, we assessed the predictors of OS and compared the results between MM and SM.

RESULTS {#s2}
=======

The median treatment period was 5.0 months (1.0--62.0) and the median follow-up period was 59.3-months (4.8--61.3). Only 20 (17.0%) patients survived this period. The median PFS and OS (equal to cancer-specific survival) were 5.6 (1.0--61.3) and 12.8 (1.0--87.2) months, respectively ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). The rate of nephrectomy and metastasectomy were 45.8% and 19.5%, respectively. Metastatic lesions were most prevalent in the lungs (72%), followed by the lymph nodes (42.4%), bone (35.6%), liver (21.2%), and brain (12.7%) ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). MM was associated with significantly higher rates of nephrectomy, TFI ≥1 year, clinical T3-4 and N1 stages, and G3-4 nuclear grades (p \< 0.05, Table [1](#T1){ref-type="table"}).

###### Comparison of baseline characteristics between metachronous (N=86) and synchronous (N=32) mRCC groups with exclude non-clear cell patients

  -------------------------------------------------------------------------------------------------------------------
                                                       Metachronous (N= 86)        Synchronous (N= 32)   P-value
  ---------------------------------------------------- --------------------------- --------------------- ------------
  Age (years)                                          58.73±10.63                 57.31±11.39           0.528^a^

  Gender (male/female)                                 69/17 (80.2/19.8)           25/7 (78.1/21.9)      0.800^b^

  Nephrectomy                                          23 (27.4)                   31 (100)              \<0.001^c^

  Metastatectomy                                       19 (22.1)                   4 (12.5)              0.303 ^c^

  TFI, ≥1yr/ \<1yr                                     5/81 (5.8/94.2)             22/10 (68.8/31.3)     \<0.001^b^

  Anemia                                               59 (68.6)                   27 (84.4)             0.088^b^

  Hypercalcemia                                        11 (13.3)                   4 (12.5)              1 ^c^

  Neutrophilia                                         13 (15.5)                   9 (28.1)              0.120^b^

  Elevated LDH                                         20 (30.8)                   6 (26.1)              0.793^b^

  KPS \> 80 /≤ 80                                      83/3 (96.5/3.5)             32/0 (100/0)          0.559^c^

  Thrombocytosis                                       11 (12.8)                   3 (9.4)               0.756 ^b^

  Creatinine                                           1.2±0.4                     1.3±0.5               0.210

  eGFR                                                 72.6±21.0                   70.7±22.2             0.667

  Metastatic lesion                                                                                      

  Lung                                                 58 (67.4)                   27 (84.4)             0.105 ^c^

  Liver                                                17 (19.8)                   8 (25.0)              0.614 ^c^

  Lymph node                                           38 (44.2)                   12 (37.5)             0.538 ^c^

  Bone                                                 31 (36.0)                   11 (34.4)             1.000 ^c^

  Brain                                                10 (11.6)                   5 (15.6)              0.547 ^c^

  Heng, Intermediate risk                              65 (75.6)                   28 (87.5)             0.159 ^b^

   Poor risk                                           21 (24.4)                   4 (12.5)              

  cT or pT stage, T1-T2/\                              42/22 (65.6/34.4)           9/15 (37.5/62.5)      0.017^b^
  T3-T4                                                                                                  

  cN or pN stage, N0/ N1/ Nx                           30/19/15 (46.9/29.7/23.4)   0/11/0 (0/100/0)      \<0.001^b^

   Fuhrman nuclear grade,                                                                                

  G1-G2/G3-G4                                          22/35 (38.6/61.4)           3/20 (13/87)          0.026 ^b^

  Treatment duration (Mos.)                            7.44±10.05                  11.96±14.69           0.116 ^a^

  Follow-up duration (Mos.)                            59.3 (4.8-60.1)             61.3 (9.4-64.3)       0.075 ^d^

  Progression-free survival (Mos)                      5.2 (1.0-60.4)              9.6 (1.0-62.0)        0.059 ^d^

  Overall survival (=Cancer specific survival, Mos.)   9.6 (1.0-62.3)              20.1 (1.5-87.2)       0.010 ^d^

  Survival/death                                       15/71 (17.4/82.6)           5/27 (15.6/84.4)      1^b^
  -------------------------------------------------------------------------------------------------------------------

a: Student\'s t-test, b: Chi-square test, c: Fisher exact test, d: Log-rank test, TFI: Treatment free interval, KPS: Karnofsky performance status, mos: months.

The median PFS and OS of SM/MM patients were 5.2 (1.0--60.4)/9.6 (1.0--62.0) (p = 0.059) and 9.6 (1.0--62.3)/20.1 (1.5--87.2) months (p = 0.010), respectively (Figure [1](#F1){ref-type="fig"}). The median PFS and OS of the intermediate-risk group (8.3/17.6 months) were significantly higher than those of the poor-risk group (2.9/4.6 months) (p \< 0.01). The PFS and OS values of SM/MM patients according to intermediate and poor Heng risk (Figure [2](#F2){ref-type="fig"}), TFI \<1 year (Figure [3](#F3){ref-type="fig"}), and TFI ≥1 year (Figure [4](#F4){ref-type="fig"}) were not significantly different (p \> 0.05), although we did not compare PFS and OS in SM patients with TFI ≥1 year owing to the small numbers of cases (Figure [4](#F4){ref-type="fig"}).

![The comparison of Kaplan Meier survival curves according to metastatic type and Heng risk groups](oncotarget-08-93633-g001){#F1}

![The comparison of Kaplan Meier survival curves according to mRCC group in each Heng risk group](oncotarget-08-93633-g002){#F2}

![Comparison of Kaplan Meier survival curves between MM and SM groups with treatment-free interval \< 1 year](oncotarget-08-93633-g003){#F3}

![Comparison of Kaplan Meier survival curves between MM and SM groups with treatment-free interval ≥ 1 year](oncotarget-08-93633-g004){#F4}

The effect of the number of Heng risk factors on PFS and OS was analyzed in SM and MM patients according to the two TFI subgroups. Increasing number of Heng risk factors had a significant effect on PFS (hazard ratio \[HR\]: 1.81; 95% confidence interval \[CI\]: 1.37--2.38) and OS (HR: 2.19; CI: 1.63--2.94) in SM patients with TFI \<1 year (p \< 0.001, Table [2](#T2){ref-type="table"}). We did not assess the effect of increasing numbers of risk factors in SM patients with TFI ≥1 year owing to small patient numbers. No significant effect of increasing numbers of Heng risk factors was observed for PFS or OS in MM (p \> 0.05, Table [2](#T2){ref-type="table"}). A Cox proportional hazards model showed that metastatic type (SM/MM) (HR: 2.72; CI: 1.64--4.51), neutrophilia (HR: 3.21; CI: 1.76--5.87), and anemia (HR: 2.48; CI: 1.49--4.13) were significant predictive factors for OS (p \< 0.05, Table [3](#T3){ref-type="table"}).

###### The hazard ratios of Heng risk factor for PFS and OS in SM/MM patients stratified by TFI

                                                       HR (95% CI)        p-value
  ------------------- ------------- ------------------ ------------------ ---------
  Total set           Synchronous   PFS                1.82 (1.38-2.39)   \<.001
                      OS            2.25 (1.67-3.04)   \<.001             
  Metachronous        PFS           0.96 (0.52-1.78)   0.999              
                                    OS                 1.13 (0.57-2.24)   0.754
  TFI \< 1 year set   Synchronous   PFS                1.81 (1.37-2.38)   \<.001
                      OS            2.19 (1.63-2.94)   \<.001             
  Metachronous        PFS           1.6 (0.58-4.43)    0.385              
                                    OS                 2 (0.65-6.19)      0.159
  TFI ≥ 1 year set    Synchronous   PFS                N.A.               N.A
                      OS            N.A.               N.A                
  Metachronous        PFS           0.93 (0.43-2.02)   0.928              
                                    OS                 1 (0.42-2.41)      0.905

HR; hazard ratio, CI; confidence interval, TFI; treatment-free interval, PFS; progression-free survival, OS; overall survival; N.A, not available due to small number of patients in SM group with TFI ≥ 1 year set.

###### The Cox proportional hazard model of predictive factors of overall survival in metastatic renal cell carcinoma

                                  Univariable                Multivariable      P-value
  ------------------------------- ------------------ ------- ------------------ ---------
  Metastatic type SM              1.84 (1.15-2.94)   0.011   2.72 (1.64-4.51)   \<0.001
  Treatment Free interval \<1yr   1.88 (1.16-3.06)   0.010                      
  Anemia                          1.87 (1.14-3.06)   0.013   2.48 (1.49-4.13)   0.001
  Hypercalcemia                   1.20 (0.69-2.09)   0.528                      
  Neutorphilia                    1.64 (0.96-2.8)    0.071   3.21 (1.76-5.87)   \<0.001
  Elevated LDH                    1.20 (0.7-2.04)    0.506                      
  KPS≤ 80                         1.50 (0.37-6.12)   0.574                      
  Thrombocytopenia                2.09 (1.10-3.99)   0.025                      

KPS, Karnofsky performance status.

DISCUSSION {#s3}
==========

Few reports have investigated the overall prognoses of metastatic types treated with TT, especially using stratification methods such as prognostic risk models \[[@R5], [@R9], [@R12]\]. Variable degrees of tumor burden, unpredictable and diverse outcomes, and the disproportionate number of SM and MM cases treated with TT have so far limited the analysis of long-term survival. Previous mRCC studies have demonstrated that MM is associated with better prognostic outcomes than SM \[[@R6]-[@R8], [@R10], [@R13], [@R16]\], but patients were not assessed using survival analysis of stratified risk factors. These previous analyses mostly involved patients with favorable and intermediate risks, resulting in better results for MM than for SM.

In the present study, anemia and neutrophilia were identified by multivariable analysis as predictive factors of overall survival, and these are known prognostic factors \[[@R22]\]. The anemia-induced hypoxic tumor microenvironment might lead to mutations, resulting in increased treatment resistance and increased metastatic potential signals, and tumor-associated neutrophilia neutrophils might be crucial for remodeling the tumor microenvironment, resulting in worse oncological features and cancer mortality \[[@R23]\]. We also collected some interesting data concerning survival between SM and MM according to different prognostic risk models and TFI \[[@R22], [@R24]\]. A significant difference in OS between MM and SM was observed, but no significant difference was observed when we stratified the data by TFI and risk factors (Figures [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}). This analysis showed that in the intermediate-risk group, SM was associated with a significant improvement in OS compared to that in the MM (21.3 vs. 13.9 months, p = 0.037; Figure [2B](#F2){ref-type="fig"}). The Cox proportional hazards model assessing the prognostic effect of the number of Heng risk factors on survival also showed significance only in SMs with TFI \<1 year (p \< 0.001), whereas MM was not significantly affected by an increasing number of Heng risk factors (p \> 0.05, Table [2](#T2){ref-type="table"}). The results of this study, when combined with those from our previous reports \[[@R12], [@R17]\], suggest that different therapeutic strategies may be required for MM and SM.

Some questions regarding the results of this study should be answered. First, what underlies the differences in survival between SM and MM despite the lack of significant differences in prognostic risk factors and TFI subgroups? The inconsistent relationship between SM/MM and OS may be explained by differences in the baseline characteristics of patients with the different metastatic types. There were more than twice as many patients with poor-risk in the SM group (24.4% vs. 12.5%, p = 0.159) (Table [1](#T1){ref-type="table"}), and an insufficient number of patients with intermediate risk may have influenced the difference in survival between patients with SM and MM.

The second issue to discuss is the fact that TFI was not a significant prognostic risk factor in this study (not selected through backward elimination, Table [3](#T3){ref-type="table"}), whereas a previous large-scale IMDC study suggested otherwise \[[@R10]\]. In this previous study, 33.2% of patients had previously received immunotherapy and 82.5% had undergone nephrectomy, whereas in the present study, only 48.1% had undergone nephrectomy and none had undergone immunotherapy. Another reason was that during TFI analysis, intermediate and poor-risk patients were re-classified according to their TFI in order to homogenize the SM and MM groups. Because TFI indirectly refers to disease aggressiveness or progression rate, which lead in turn to unfavorable OS in mRCC \[[@R25]\], there were insignificant differences in survival between the SM and MM groups when controlling for growth rate and tumor activity. However, SM and MM patients with a TFI \<1 year had worse PFS/OS than those with a TFI ≥1 year (Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}). Furthermore, an increasing number of Heng risk factors significantly and negatively affected OS only in SM patients with TFI \<1 year (p \< 0.001, Table [2](#T2){ref-type="table"}). In those with TFI ≥1 year, intermediate-risk mRCC was associated with a similar median OS in MM and SM, suggesting that the TT strategy may be similar in those with slowly progressing mRCC regardless of metastatic type. Meanwhile, a different strategy may be applied in cases of MM and SM in patients in whom mRCC is progressing faster (TFI \<1 year). Considering the results of the present study and those of previous tissue microarray and clinicopathological studies \[[@R12], [@R17], [@R21], [@R24]\], TT strategies should be developed with consideration of the patient's metastatic type and TFI.

The small number of poor-risk patients precluded the analysis of survival in patients with TFI ≥1 year (Figure [3](#F3){ref-type="fig"}) because most patients with poor risk were in the SM with TFI \<1 year group (24.4% vs. MM 12.5%), and no prognostic differences were observed between SM and MM. Those with poor risk were mostly in a bad general condition, with anemia and neutrophilia, and had fast-developing disease. We believe that the TT strategy for poor-risk patients should focus on improving the patient's general condition while taking into account the tolerability of target agents, and should attempt to suppress the fast-growing tumor. Future, large-scale, translational analyses, including genetic analysis and novel metabolic assessment techniques, will be needed.

Another difference between SM and MM is the presence or absence of primary tumors following nephrectomy. In the present study, in all patients with MM who had undergone nephrectomy, MM was detected early during a regular follow-up after nephrectomy, and the disease had a lower tumor burden than SM, which was associated with the tumor burden of the primary tumor and a relatively large tumor burden in the metastatic tumor. Our additional analysis of nephrectomy in patients with SM and MM showed that the SM (20.0 months) and MM (20.1 months) groups were associated with similar median values of OS (data not shown). The degree of tumor burden, including that of the primary tumor, was an important prognostic factor. This implies that mRCC treated by TT once the primary tumor has been removed is associated with similar prognoses regardless of metastatic type. Furthermore, cytoreductive nephrectomy seems to be a more important prognostic factor for mRCC \[[@R26], [@R27]\]. The decreased tumor burden that occurred with the disappearance of the primary tumor lesion provided better prognostic outcomes with systemic TT. However, good performance status and a primary tumor accounting for \>75% of the overall tumor burden without any metastatic lesions in the central nervous system and liver did not yield a better prognostic outcome for every mRCC patient after cytoreductive nephrectomy, which resulted in a low rate of nephrectomy in the targeted era \[[@R28], [@R29]\].

The current study was limited in a few key ways, mainly by the retrospective study design and small number of enrolled patients in each mRCC group, especially in the SM and poor-risk groups. The intermediate-risk group should ideally be investigated according to pathophysiologic characteristics between and within primary tumors after nephrectomy and metastatic tumors after metastasectomy, especially in the case of MM. Metabolic tumor activity, nephrectomy, overall tumor burden including that of metastatic organs, gene sequencing analysis, and the effect of different medical targeted agents were not considered in our analysis.

In conclusion, the metastatic type (SM or MM) of mRCC appears to be a significant prognostic risk factor in TT-treated mRCC patients. A non-significant favorable survival trend was observed in patients with MM, especially in intermediate-risk patients. However, after stratifying patients according to TFI, the Heng intermediate-risk group was not associated with any significant differences between SM and MM patients with TFI \<1 year. This may suggest that TFI, or the rate of progression, has a greater influence on survival than metastatic type. However, based on the findings of this study, we suggest that both metastatic type and TFI should be considered when clinicians develop TT strategies for their patients.

MATERIALS AND METHODS {#s4}
=====================

Ethics statement {#s4_1}
----------------

The institutional review board of the National Cancer Center (IRB No. NCC2016-0263) approved this retrospective study, and waived the requirement for written informed consent. All patient data were anonymized and de-identified prior to analysis. All study protocols were performed in accordance with the ethical tenets of the Declaration of Helsinki.

Patient characteristics {#s4_2}
-----------------------

From 2005 to 2014, we retrospectively reviewed 93 (78.8%) intermediate (1--2 Heng risk factors) and 25 (21.2%) poor (≥3 Heng risk factors) Heng risk patients, including 32 MM patients (27.1%) and 86 SM patients (72.9%). The exclusion criteria were non-clear cell RCC and favorable risk, because the SM group consisted only of intermediate-risk and poor-risk patients. The patients' baseline information, including the metastatic lesions, rate of nephrectomy, and metastasectomy, are described in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}. The choice of systemic VEGF-target agents was made at the discretion of the treating urologist (JC) according to pathological findings and the patient's national insurance coverage, as cited in a previous study \[[@R17]\].

The International Metastatic Renal Cell Carcinoma Database Consortium risk (IMDC risk, also known as the Heng risk) criteria \[[@R10]\] were used for prognostic risk stratification to predict the response to systemic therapy among patients with mRCC. Prognostic factors from the Heng risk criteria included hemoglobin level \< lower normal limit, Karnofsky performance score \<80%, thrombocytosis \> upper normal limit (ULN), neutrophilia \> ULN, hypercalcemia \> ULN, and \<1 year from diagnosis to treatment (or treatment-free interval, TFI). Fuhrman nuclear grade \[[@R18]\] and TNM stages from the latest International Union Against Cancer classification (2009) \[[@R19], [@R20]\] were used for pathological RCC evaluation. We used the RECIST criteria v1.1 to evaluate treatment response \[[@R21]\]. All intermediate- and poor-risk mRCC patients underwent a complete evaluation after every two cycles of TT. The follow-up protocol, including all laboratory and imaging evaluations, were based on cycles of target agents described previously \[[@R17]\]. Treatment continued until disease progression was identified using RECIST criteria. Disease progression was defined as at least a 20% increase in the sum of the longest diameter of target lesions in CT imaging.

Statistical analysis {#s4_3}
--------------------

Descriptions of the baseline characteristics are presented as a median with range (min-max) for continuous variables and a frequency with percentage for categorical variables. The comparison between SM and MM was performed using Student's t-test for continuous variables and Pearson's Chi-square test or Fisher's exact test as appropriate. For PFS and OS, the survival curves were estimated using Kaplan-Meier method and differences between groups were tested using the log-rank test. The survival curves between SM and MM were also compared in subgroups of patients stratified by Heng risk groups (intermediate or poor) and TFI (\< 1yr or ≥1yr). The univariable Cox proportional hazard model was performed to estimate the hazard ratio for each 1-unit increase in the Heng risk factors and other risk factors. Variables with a p-value \< 0.2 from the univariable model were selected, and the multivariable Cox proportional hazard model was fitted using a backward variable selection method with an elimination criterion of p-value \> 0.05. P-values less than 0.05 were considered statistically significant. Statistical analyses were performed using SAS (version 9.3; SAS Institute Inc., Cary, NC, USA) and R-project for statistical computing (version 3.3.2).
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